<DOC>
	<DOCNO>NCT00557830</DOCNO>
	<brief_summary>The primary objective study compare effectiveness dose-escalation regimen ( 400 800mg bid ) relative standard dose regimen ( 400mg bid ) sorafenib give patient metastatic RCC . The secondary objective evaluate effect dose-escalation regimen quality life ( QoL ) patient metastatic RCC characterize safety tolerability profile dose-escalation regimen sorafenib patient metastatic RCC .</brief_summary>
	<brief_title>Randomized Study Sorafenib Dose Escalation Patients With Previously Untreated Metastatic Renal Cell Carcinoma</brief_title>
	<detailed_description />
	<mesh_term>Carcinoma</mesh_term>
	<mesh_term>Carcinoma , Renal Cell</mesh_term>
	<mesh_term>Sorafenib</mesh_term>
	<mesh_term>Niacinamide</mesh_term>
	<criteria>Age ≥18 year old . Diagnosis unresectable/metastatic renal cell carcinoma ( RCC ) . Nonclear cell histology permit ( except medullary , collect duct , sarcomatoid &gt; 50 % specimen ) . Prior metastasectomy permit long measurable disease time consent . Karnofsky Performance Status 50 % great study entry . Adequate bone marrow , liver renal function assess follow : Hemoglobin ≥ 9.0 g/dL . ANC ≥ 1500/mm3 . Platelet count ≥ 100,000/mm3 . Total bilirubin ≤ 1.5 ULN . ALT AST ≤ 2.5 × ULN ( ≤ 5 × ULN patient liver involvement ) . Creatinine ≤ 1.5 × ULN . Women childbearing potential must negative serum urine pregnancy test perform within 7 day prior start treatment . Women childbearing potential sexually active men must agree use adequate barrier contraception prior study entry , duration study participation , least three month last administration sorafenib . INR &lt; 1.5 PT/ PTT within normal limit . Patients receive anticoagulation treatment agent warfarin heparin may allow participate . For patient warfarin , INR measure prior initiation sorafenib monitor least weekly , define local standard care , INR stable . Ability understand willingness sign write informed consent . A sign informed consent must obtain prior study specific procedure . Prior systemic anticancer treatment metastatic disease , include investigational therapy . Prior treatment bevacizumab , sunitinib , sorafenib even adjuvant setting . Prior cytokine therapy interleukin ( IL ) 2 interferon ( IFN ) metastatic disease . Active malignancy RCC ( except nonmelanoma skin cancer ) within 5 year enrollment . Hemodialysis peritoneal dialysis . Treatment radiotherapy within 2 week enrollment . Cardiac disease : Congestive heart failure Class II high per NYHA . Patients must unstable angina ( anginal symptom rest ) new onset angina ( begin within last 3 month ) myocardial infarction within past 6 month . Uncontrolled CNS metastasis . All patient must undergo CT ) scan/MRI brain exclude brain metastasis . Patients adequately treat CNS disease may consider participation long first dose sorafenib 4 week completion CNS therapy . Uncontrolled hypertension define SBP &gt; 150 mmHg DBP &gt; 90 mmHg , despite optimal medical management . Active clinically serious infection &gt; Grade 2 per CTCAE v3 . Thrombolic embolic event cerebrovascular accident include transient ischemic attack within past 6 month . Pulmonary hemorrhage/bleeding event ≥ Grade 2 per CTCAE v3.0 within 4 week administration first dose study drug . Any hemorrhage/bleeding event ≥ Grade 3 per CTCAE v3.0 within 4 week administration first dose study drug . Serious nonhealing wound , ulcer , bone fracture . Evidence history bleed diathesis coagulopathy . Major surgery , open biopsy significant traumatic injury within 4 week administration first study drug dose . Use St. John 's Wort , rifampin ( rifampicin ) , phenytoin , Phenobarbital , carbamazepine , dexamethasone . Known suspected allergy sorafenib agent give course trial . Any condition impair patient 's ability swallow whole pill . Any malabsorption problem . Pregnancy lactation .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2013</verification_date>
	<keyword>Renal Cell Carcinoma</keyword>
	<keyword>Kidney Cancer</keyword>
</DOC>